Comparison Chart PHAXIAM Therapeutics S.A. Euronext Paris

Equities

Real-time Euronext Paris Other stock markets 05:37:02 2024-05-13 am EDT			5-day change	1st Jan Change
2.975 ^EUR	+0.17%		+1.71%	-35.33%

Apr. 15	Phaxiam initiates trial in infective endocarditis	CF
Apr. 15	PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes

		Sector	Change	5d. change	1st Jan change	1-year change	5-years change	Capi.	ST	MT	LT
	PHAXIAM THERAPEUTICS S.A.	Bio Therapeutic Drugs	+0.17%	+1.71%	-35.33%	-71.06%	-95.39%	19.43M